Reviews Bloodborne, Sales the order 1886
Please excuse my (probally) poor grammar
What is the biggest game in the first quarter of 2015? | |||
| The Order 1886 (PS4) | 70 | 25.09% | |
| Final Fantasy Type 0 (PS4 & X1) | 10 | 3.58% | |
| Bloodborne (PS4) | 94 | 33.69% | |
| Dragon Quest Heroes (from Japan) | 3 | 1.08% | |
| Dying Light (PS4 & X1) | 6 | 2.15% | |
| Project Cars (PS4 & X1) | 4 | 1.43% | |
| One Piece Pirate Warriors 3 (from Japan) | 2 | 0.72% | |
| Evolve (PS4 & X1) | 22 | 7.89% | |
| see results | 25 | 8.96% | |
| A other game | 42 | 15.05% | |
| Total: | 278 | ||
Reviews Bloodborne, Sales the order 1886
Please excuse my (probally) poor grammar
| Bman54 said: Even though I don't want it at all, Bloodborne seems to be the most hyped game, with Evolve being not too far behind. For me personally, it's between Dying Light and The Order. |
i think, 2014 has "evolve" hype, but now, not anymore. what do you think now?
majoras mask is not a "brandnew" game, right ?

really surprised majoras mask is not on there. lol. after how much people have been clamoring for it for so long
In terms of sales? Battlefield Hardline without a doubt, at least in the short run. Something like Mario Party 10 or Bloodbourne good win in the long run, but seeing as how Battlefield 4 sold over 12 million and other big series like Call of Duty have only had somewhat hurt sales regardless of acclaim, I doubt it..
Most definitely Bloodborne. I can see commercial and critical success. Of that list you posted as cliche as it sounds, The Order would be runner up since both are exclusive new IPs. The poll results also seem to reflect that :P
| aLkaLiNE said: Most definitely Bloodborne. I can see commercial and critical success. Of that list you posted as cliche as it sounds, The Order would be runner up since both are exclusive new IPs. The poll results also seem to reflect that :P |
you are right, yes.

About Us |
Terms of Use |
Privacy Policy |
Advertise |
Staff |
Contact
Display As Desktop
Display As Mobile
© 2006-2026 VGChartz Ltd. All rights reserved.